Gabriela Borsaru

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features.

Nicoletta Testoni, Gabriela Borsaru, Giovanni Martinelli et al. · PubMed · 1999 · 91 citations

FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk

Michele Spina, Zoltán Nagy, Josep‐María Ribera et al. · Annals of Oncology · 2015 · 84 citations · Full text

Lymphoid Neoplasia, Urology, Febuxostat Versus Allopurinol +12

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i> . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

María‐Victoria Mateos, Tamás Masszi, Norbert Grząśko et al. · Haematologica · 2017 · 54 citations · Full text

Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.

Giovanni Martinelli, Emanuela Ottaviani, Silvia Buonamici et al. · PubMed · 2003 · 47 citations